Table of Contents
Table of Contents
Preface
Chapter 1. Comparative Pharmacology of P2Y12 Inhibitors
(Maria E. Tsoumani, PhD, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece)
Chapter 2. Clopidogrel in Coronary Artery Disease: A Review of the Randomized Trials
(Ryan Watson, Michael P. Savage, David L. Fischman, Department of Medicine, Division of Cardiology, Thomas Jefferson University, Philadelphia, PA, US)
Chapter 3. Optimizing DAPT Duration after PCI: From Randomized Controlled Trials to Individualized Net Clinical Benefit
(Enrico G. Ferro, MD, Usman A. Tahir, MD, Robert W. Yeh MD, Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts)
Chapter 4. Platelet Function Tests to Assess Response to P2Y12 Inhibitors and Personalised Antiplatelet Therapy in Clinical Practice
(Bartosz Olechowski, MD, Nick Curzen, PhD, Coronary Research Group, University Hospital Southampton NHS Foundation Trust, Southampton, UK, and others)
Chapter 5. P2Y12 Inhibitors in the Setting of Coronary Artery Bypass Graft Surgery
(Heerajnarain Bulluck, PhD, and Alex Sirker, PhD, Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK, and others)
Chapter 6. The Role of Anti-Platelets and Anti-Coagulants in Peripheral Vascular Disease
(Uzair Ashraf, MD, Nureddin Almaddah, MD, Amit Nanda, MD, Rafik ElBeblawy, MD, and Rami N. Khouzam, University of Tennessee Health Science Center, Department of Medicine, Memphis, TN, US, and others)
Chapter 7. Clopidogrel in the Management of Neurovascular Disease
(Diana L. Tzeng, MD, Robin N. Dharia MD, Shaista Alam MD, Rodney D. Bell, MD, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, US)
Chapter 8. Antiplatelet Therapy after Structural Heart Interventions
(Vincent Nguyen, MD, and Nicholas J. Ruggiero II, MD, Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, US)
Chapter 9. Antiplatelet Therapy in Patients Receiving Anticoagulation
(Fahad Alkhalfan, MD, Mathieu Kerneis, MD, Tarek Nafee, MD, Sudarshana Datta, MD, M. Khurram Afzal, MD, C. Michael Gibson, MD, From a the Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US)
Chapter 10. The Role of Newer P2Y12 Inhibitors in Acute Coronary Syndromes
(Mohamed O. Mohamed and Mamas A. Mamas, DPhil, Department of Cardiology, Keele University, Keele, UK)
Chapter 11. Cangrelor: A Novel Intravenous P2Y12 Inhibitor
(Timothy Barry, MD, Sheldon Goldberg, MD, Department of Cardiology, Pennsylvania Hospital, Philadelphia, PA, US)
Chapter 12. Clopidogrel Resistance
(Udaya S Tantry, Kevin P Bliden, Eliano P Navarese, Paul A Gurbel, Platelet and Thrombosis Research, Lutherville, MD, US, and others)
Chapter 13. Management of Clopidogrel Hypersensitivity
(Alec Vishnevsky, MD, Henry Siu MD, Nicholas J. Ruggiero, MD, Paul Walinsky, MD, David L. Fischman, MD, and Michael P. Savage, MD, Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, US, and others)
Chapter 14. Antiplatelet Therapy and Subsequent Bleeding: Incidence, Prediction and Its Effect on Outcomes
(Tim Kinnaird, Department of Cardiology, Cardiff, UK)
About the Editors
Index